Patents Assigned to UNIVERSITAET ZUERICH PROREKTORAT MNW
  • Publication number: 20140141522
    Abstract: A method for selective detection of cyanide in a sample comprises determining a color change of a corrinoid compound caused upon contact with the sample. A high detection sensitivity and selectivity are achieved by having the corrinoid compound adsorbed on a solid phase. This general principle is applied in a kit for selective detection of cyanide and to uses thereof. One application consists in a device for removing hydrogen cyanide from a gaseous phase, e.g. tobacco smoke.
    Type: Application
    Filed: April 5, 2012
    Publication date: May 22, 2014
    Applicant: UNIVERSITAET ZUERICH PROREKTORAT MNW
    Inventors: Felix Zelder, Christine Männel-Croisé
  • Patent number: 8680042
    Abstract: Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
    Type: Grant
    Filed: April 18, 2010
    Date of Patent: March 25, 2014
    Assignee: Universität Zürich Prorektorat MNW
    Inventors: Anna Yulienva Bogdanova, Max Gassman, Jeroen Goede
  • Publication number: 20140073575
    Abstract: Prolyl and lysyl hydroxylases isolated from Mimivirus are described. These are able to hydroxylate collagen. Isolated nucleic acids coding for the mentioned hydroxylases are incorporated into suitable vectors and used to express these hydroxylases in host cells, e.g. E. coli. Furthermore a method of manufacturing hydroxylated collagen in a host cell is described. The hydroxylases and the recombinantly expressed hydroxylated collagen are useful in clinical settings and biotechnology applications.
    Type: Application
    Filed: March 21, 2012
    Publication date: March 13, 2014
    Applicant: UNIVERSITAET ZUERICH PROREKTORAT MNW
    Inventors: Thierry Hennet, Christoph Rutschmann, Kelvin Luther